Skip to content
ppharmaranks
Menu
Class IIOngoing

Blemish Spot Treatment (Salicylic Acid) 1% recall

FDA recall D-0487-2026 · initiated Apr 1, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Apr 22, 2026How we research

Island Kinetics, Inc. d.b.a. CoValence Laboratories recalled Blemish Spot Treatment (Salicylic Acid) 1% in Apr 2026 — an FDA Class II recall (D-0487-2026) because Failed Stability Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Stability Specifications

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot#: 4228D2, 4229D1, Exp.: 07/31/2026 Lot#: 5147D2, Exp.: 04/30/2027

Quantity recalled: 28,163 bottles

Details

Product
Blemish Spot Treatment (Salicylic Acid) 1%, .5 fl oz (15 ml) bottles, Skin Script, Chandler, AZ 85226, UPC 6 10563 13873 9.
Recalling company
Island Kinetics, Inc. d.b.a. CoValence Laboratories
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
U.S. Nationwide
Initiated
Apr 1, 2026
FDA report date
Apr 22, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Blemish Spot Treatment (Salicylic Acid) 1% recalled?
Island Kinetics, Inc. d.b.a. CoValence Laboratories recalled Blemish Spot Treatment (Salicylic Acid) 1% in Apr 2026 — an FDA Class II recall (D-0487-2026) because Failed Stability Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Blemish Spot Treatment (Salicylic Acid) 1% recalled?
Per the FDA enforcement record, the reason for recall D-0487-2026 was: Failed Stability Specifications
Is a recalled Blemish Spot Treatment (Salicylic Acid) 1% dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Blemish Spot Treatment (Salicylic Acid) 1% are affected?
Distributed: U.S. Nationwide. The recall covers these lots — Lot#: 4228D2, 4229D1, Exp.: 07/31/2026 Lot#: 5147D2, Exp.: 04/30/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0487-2026.

Source: openFDA Drug Enforcement record D-0487-2026

← All drug recalls